Should the implantable cardiac defibrillator be used for primary prevention of sudden death? A review of the issues relevant to hospital decision making

Canadian Journal of Cardiology

Volumn 20, Issue 12, 2004, Pages 1199-1204

  McGregor, Maurice ^a,b   Chen, Jun ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cost effectiveness; Ethics; Health policy; Health Technology Assessment; Implantable cardiac defibrillator; Legal issues

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CANADA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATION; DEFIBRILLATOR; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEART DEATH; HEART INFARCTION; HUMAN; LEGAL ASPECT; MEDICAL DECISION MAKING; MEDICAL ETHICS; MORTALITY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; SUDDEN DEATH;

EMPIRICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH;

BUDGETS; COST-BENEFIT ANALYSIS; DEATH, SUDDEN; DECISION MAKING, ORGANIZATIONAL; DEFIBRILLATORS, IMPLANTABLE; ETHICS, INSTITUTIONAL; FEMALE; HOSPITAL ADMINISTRATION; HOSPITAL COSTS; HUMANS; MALE; ORGANIZATIONAL POLICY; PRIMARY PREVENTION; QUALITY OF LIFE; QUEBEC; RISK ASSESSMENT; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 9144257928     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. McGregor M, Chen J. Use of the implantable cardiac defibrillator (ICD) at the McGill University Health Centre (MUHC). A technology assessment. The McGill University Health Centre, Montreal, Quebec. . (Version current at August 30, 2004).
2. State-specific mortality from sudden cardiac death - United States, 1999. MMWR Moth Mortal Wkly Rep 2002;51:123-6.
3. Gardner MJ, Leather R, Teo K. Epidemiology. Can J Cardiol 2000;16(Suppl C):10C-2C.
4. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002;106:2145-61.
5. Moss AJ, Zareba W, Hall J, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
6. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071-8.
7. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-84.
8. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-54.
9. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardiovascular defibrillator against amiodarone. Circulation 2000;101:1297-302.
10. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-24.
11. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death. A meta-analysis. J Am Coll Cardiol 2003;41:1573-82.
12. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
13. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Archery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997;337:1569-75.
14. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.
15. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation 2002;105:1453-8.
16. Bardy GH. SCD-HeFT: The Sudden Cardiac Death in Heart Failure Trial. (Version current at September 14, 2004).
17. Moss AJ; Multicenter Automatic Defibrillator Implantation Trial. MADIT-II and its implications. Eur Heart J 2003;24:16-8.
18. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989;149:1785-9.
19. Frasure-Smith N, Lesperance F, Juneau M, Talajic M, Bourassa MG. Gender, depression, and one-year and prognosis after myocardial infarction. Psychosom Med 1999;61:26-37.
20. Conti JB. Psychological complications of implantable cardioverter-defibrillator therapy. Card Electrophysiol Rev 1998;2:342-44.
21. Irvine J, Dorian P, Smith J, et al. Quality of life comparison between the implantable cardioverter defibrillator and amiodarone. Psychosom Med 1999;61:114.
22. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105:589-94.
23. Mushlin AI, Hall J, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 1998;97:2129-35.
24. O'Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: Results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001;103:1416-28.
25. Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 2002;105:2049-57.
26. La Rovere MT, Pinna GT, Mastri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003;107:565-70.
27. Hohnloser SH, Ikeda T, Bloomfield DM, Dabbous OH, Cohen RJ. T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. Lancet 2003;362:125-6.
28. Zareba W. Multicenter automatic defibrillator implementation trial (MADIT) II results. North American Society of Pacing and Etectrophysiology, 23rd Annual Scientific Sessions. http://www.medscape.com/viewarticle/433738.
29. Shenkman HJ, Pampati V, Khandewal AK, et al. Congestive heart failure and QRS duration: Establishing prognosis study. Chest 2002;122:528-34.
30. Kalra PR, Sharma R, Shamin W, et al. Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. Int J Cardiol 2002;86:225-31.
31. Brilakis ES, Mavrogiorgos NC, Kopecky SL, et al. Usefulness of QRS duration in the absence of bundle branch block as an early predictor of survival in non-ST elevation acute myocardial infarction. Am J Cardiol 2002;89:1013-8.
32. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN; Department of Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002;143:1085-91.
33. Silvet H, Amin J, Padmanabhan S, Pai RG. Prognostic implications of increased QRS duration in patients with moderate and severe left ventricular systolic dysfunction. Am J Cardiol 2001;88:182-5.
34. Hoffmaster B. Chapter 4. The ethics of setting limits on ICD therapy. Can J Cardiol 2000;16:1313-7.
35. Dickens BM. Chapter 5. Legal implications of ICD therapy. Can J Cardiol 2000;16:1319-24.